Solid Biosciences Inc (SLDB)

Apr 8, 2025, 4:50 PM EDT - 15 days ago

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Apr 1, 2025, 8:00 AM EDT - 22 days ago

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 2:25 PM EDT - 23 days ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SRPT TSHA XBI

Mar 12, 2025, 8:00 AM EDT - 6 weeks ago

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 6, 2025, 4:16 PM EST - 6 weeks ago

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 5, 2025, 8:00 AM EST - 7 weeks ago

Solid Biosciences to Participate at Upcoming Investor Conferences

Feb 18, 2025, 12:29 PM EST - 2 months ago

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

Feb 18, 2025, 7:00 AM EST - 2 months ago

Solid Biosciences Announces Pricing of Underwritten Offering

Feb 18, 2025, 6:45 AM EST - 2 months ago

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Jan 21, 2025, 6:27 PM EST - 3 months ago

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Jan 21, 2025, 8:30 AM EST - 3 months ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Jan 15, 2025, 4:05 PM EST - 3 months ago

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Jan 8, 2025, 4:05 PM EST - 3 months ago

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:15 PM EST - 3 months ago

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Dec 23, 2024, 4:05 PM EST - 4 months ago

Solid Biosciences Added to the Nasdaq Biotechnology Index

Dec 13, 2024, 1:52 PM EST - 4 months ago

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Nov 14, 2024, 8:00 AM EST - 5 months ago

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Nov 6, 2024, 4:05 PM EST - 6 months ago

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 12, 2024, 8:00 AM EDT - 7 months ago

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 4:08 PM EDT - 9 months ago

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 1, 2024, 4:19 PM EDT - 10 months ago

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2024, 7:52 AM EDT - 1 year ago

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

Apr 10, 2024, 7:32 PM EDT - 1 year ago

Buy Solid Biosciences: Unpacking Its Main Value Driver

Apr 1, 2024, 7:45 AM EDT - 1 year ago

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Mar 13, 2024, 7:44 AM EDT - 1 year ago

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Jan 16, 2024, 11:01 PM EST - 1 year ago

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Jan 16, 2024, 8:00 AM EST - 1 year ago

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Jan 8, 2024, 7:09 AM EST - 1 year ago

Solid Biosciences Announces $109 Million Private Placement

Nov 22, 2023, 8:00 AM EST - 1 year ago

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Nov 8, 2023, 4:17 PM EST - 1 year ago

Solid Biosciences Provides Third Quarter Business Update and Financial Results

Oct 2, 2023, 8:00 AM EDT - 1 year ago

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

Aug 14, 2023, 4:17 PM EDT - 1 year ago

Solid Biosciences Provides Second Quarter Business Update and Financial Results

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate at the Jefferies Healthcare Conference

May 22, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit

May 16, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

May 11, 2023, 7:30 AM EDT - 2 years ago

Solid Biosciences Provides First Quarter Business Update and Financial Results

May 8, 2023, 4:05 PM EDT - 2 years ago

Solid Biosciences to Present at JMP Securities Life Sciences Conference

Apr 21, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 13, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference

Mar 23, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

Mar 21, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery

Mar 7, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences to Present at Barclays Global Healthcare Conference

Feb 8, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences to Present at SVB Securities Global Biopharma Conference

Jan 26, 2023, 8:00 AM EST - 2 years ago

Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA's Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy

Jan 11, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Jan 9, 2023, 4:26 PM EST - 2 years ago

Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer

Jan 9, 2023, 8:01 AM EST - 2 years ago

Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer

Jan 9, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 5, 2022, 7:30 AM EST - 2 years ago

Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement

Dec 1, 2022, 4:15 PM EST - 2 years ago

Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio